Endovascular navigation technology clears first preclinical study
Endovascular repair of aortic aneurysms and dissections is critically dependent on optimal understanding of the patient’s vasculature. To that end, Cleveland Clinic Innovations spinoff company Centerline Biomedical Inc. is refining development of its Intraoperative Positioning System (IOPS), a novel endovascular navigation technology developed by Cleveland Clinic researchers.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
IOPS extracts the centerlines of the aorta and branch vessels from a patient’s CT and then mathematically constructs a high-quality three-dimensional model of the relevant vasculature, as shown in the image above. Electromagnetic tracking technology allows the model to be used in a GPS-like fashion to guide surgeons during minimally invasive endovascular aortic repairs, enabling less reliance on X-ray fluoroscopy.
The first preclinical in vivo study of IOPS was completed in May 2016 at Cleveland Clinic Lerner Research Institute. It demonstrated the system’s ability to provide non-radiation-based navigation with superior visualization compared with X-ray fluoroscopy, which is limited by its two-dimensional visualization and by the radiation exposure it confers on patients and providers.
“Preclinical evaluation verified the ability to use this navigation system in manipulating through the aorta and its branches in the absence of radiation-inducing fluoroscopy,” says Cleveland Clinic vascular surgeon Matthew Eagleton, MD, who led the study. Noting that catheters and guidewires were easily visualized on the IOPS display, he predicted that the system “will be a game changer in the era of endovascular therapy.”
Centerline Biomedical plans to submit IOPS for FDA review, with a target market entry in the third quarter of 2017.
Advertisement
Advertisement
Safety and efficacy are comparable to open repair across 2,600+ cases at Cleveland Clinic
How and why Cleveland Clinic achieves repair in 99% of patients
Multimodal evaluations reveal more anatomic details to inform treatment
Insights on ex vivo lung perfusion, dual-organ transplant, cardiac comorbidities and more
CD36 loss-of-function variant accounts for large portion of risk in this population
Series of 145 patients characterizes scope of presentations, interventions and outcomes
Microvascular “supercharging” is a critical newer step to promote favorable outcomes
Why Cleveland Clinic is launching its cardioimmunology center